Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S. Tharkar-Promod S, et al. Among authors: deininger mw. Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5. Leukemia. 2018. PMID: 28579617 Free PMC article.
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T. Qiang W, et al. Among authors: deininger mw. Leukemia. 2017 Dec;31(12):2844-2847. doi: 10.1038/leu.2017.264. Epub 2017 Aug 18. Leukemia. 2017. PMID: 28819281 Free PMC article. Clinical Trial. No abstract available.
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW. Eiring AM, et al. Among authors: deininger mw. Leukemia. 2015 Dec;29(12):2328-37. doi: 10.1038/leu.2015.196. Epub 2015 Jul 23. Leukemia. 2015. PMID: 26202934 Free PMC article.
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW. Eiring AM, et al. Among authors: deininger mw. Leukemia. 2015 Mar;29(3):586-597. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19. Leukemia. 2015. PMID: 25134459 Free PMC article.
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Yan D, Pomicter AD, O'Hare T, Deininger MW. Yan D, et al. Among authors: deininger mw. Clin Cancer Res. 2019 Nov 15;25(22):6561-6563. doi: 10.1158/1078-0432.CCR-19-2270. Epub 2019 Sep 20. Clin Cancer Res. 2019. PMID: 31540978 Free PMC article.
261 results